<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Diabetes Obes Metab</journal-id><journal-id journal-id-type="iso-abbrev">Diabetes Obes Metab</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1463-1326</journal-id><journal-id journal-id-type="publisher-id">DOM</journal-id><journal-title-group><journal-title>Diabetes, Obesity &#x00026; Metabolism</journal-title></journal-title-group><issn pub-type="ppub">1462-8902</issn><issn pub-type="epub">1463-1326</issn><publisher><publisher-name>Blackwell Publishing Ltd</publisher-name><publisher-loc>Oxford, UK</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27027802</article-id><article-id pub-id-type="pmc">5111732</article-id><article-id pub-id-type="doi">10.1111/dom.12669</article-id><article-id pub-id-type="publisher-id">DOM12669</article-id><article-categories><subj-group subj-group-type="overline"><subject>Research Letter</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Letters</subject></subj-group></article-categories><title-group><article-title>Relationship of body mass index with efficacy of exenatide twice daily added to insulin glargine in patients with type 2 diabetes</article-title><alt-title alt-title-type="left-running-head">Wolffenbuttel et al.</alt-title></title-group><contrib-group><contrib id="dom12669-cr-0001" contrib-type="author" corresp="yes"><name><surname>Wolffenbuttel</surname><given-names>B. H. R.</given-names></name><xref ref-type="aff" rid="dom12669-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="dom12669-cr-0002" contrib-type="author"><name><surname>Van Gaal</surname><given-names>L.</given-names></name><xref ref-type="aff" rid="dom12669-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="dom12669-cr-0003" contrib-type="author"><name><surname>Dur&#x000e1;n&#x02010;Garcia</surname><given-names>S.</given-names></name><xref ref-type="aff" rid="dom12669-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="dom12669-cr-0004" contrib-type="author"><name><surname>Han</surname><given-names>J.</given-names></name><xref ref-type="aff" rid="dom12669-aff-0004">
<sup>4</sup>
</xref></contrib></contrib-group><aff id="dom12669-aff-0001"><label><sup>1</sup></label><named-content content-type="organisation-division">Department of Endocrinology</named-content><institution>University of Groningen, University Medical Center Groningen</institution><named-content content-type="city">Groningen</named-content><country country="NL">The Netherlands</country></aff><aff id="dom12669-aff-0002"><label><sup>2</sup></label><named-content content-type="organisation-division">Department of Endocrinology, Diabetology, and Metabolism</named-content><institution>Antwerp University Hospital</institution><named-content content-type="city">Antwerp</named-content><country country="BE">Belgium</country></aff><aff id="dom12669-aff-0003"><label><sup>3</sup></label><institution>Unidad de Gestion de Endocrinolog&#x000ed;a y Nutrici&#x000f3;n</institution><named-content content-type="organisation-division">Hospital Universitario Virgen de Valme</named-content><named-content content-type="city">Seville</named-content><country country="ES">Spain</country></aff><aff id="dom12669-aff-0004"><label><sup>4</sup></label><institution>Pharmapace, Inc</institution><named-content content-type="city">San Diego</named-content><named-content content-type="country-part">CA</named-content><country country="US">USA</country></aff><author-notes><corresp id="correspondenceTo"><label>*</label><italic>Correspondence to</italic>: B. H. R. Wolffenbuttel, Department of Endocrinology, University of Groningen, University Medical Center Groningen, HPC AA31, Groningen 9700 RB, The Netherlands.<break/>
E&#x02010;mail: <email>bwo@umcg.nl</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>18</day><month>5</month><year>2016</year></pub-date><pub-date pub-type="ppub"><month>8</month><year>2016</year></pub-date><volume>18</volume><issue>8</issue><issue-id pub-id-type="doi">10.1111/dom.2016.18.issue-8</issue-id><fpage>829</fpage><lpage>833</lpage><history><date date-type="received"><day>06</day><month>1</month><year>2016</year></date><date date-type="rev-recd"><day>21</day><month>3</month><year>2016</year></date><date date-type="accepted"><day>22</day><month>3</month><year>2016</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2016 John Wiley & Sons Ltd <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2016 The Authors. Diabetes, Obesity and Metabolism published by John Wiley &#x00026; Sons Ltd.</copyright-statement><license license-type="creativeCommonsBy-nc"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">Creative Commons Attribution&#x02010;NonCommercial</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:DOM-18-829.pdf"/><abstract id="dom12669-abs-0001"><p id="dom12669-para-0003">This <styled-content style="italic-in-any-context">post hoc</styled-content> analysis assessed the evidence behind common reimbursement practices by evaluating the relationship of body mass index (<styled-content style="fixed-case">BMI</styled-content>) ranges (&#x0003c;30, 30&#x02013;35 and &#x0003e;35 kg/m<sup>2</sup>) with treatment effects of exenatide twice daily among patients with type 2 diabetes. Patients received exenatide twice daily added to insulin glargine in two 30&#x02010;week studies (exenatide twice daily vs insulin lispro, n = 627; exenatide twice daily vs placebo, n = 259). No association of baseline <styled-content style="fixed-case">BMI</styled-content> with changes in efficacy variables was observed. Glycated haemoglobin (<styled-content style="fixed-case">HbA1c</styled-content>) reductions were significant (p <styled-content style="italic-in-any-context">&#x0003c;</styled-content> 0.0001) and similar across <styled-content style="fixed-case">BMI</styled-content> range groups in the lispro&#x02010;comparator study and greater for exenatide versus placebo in the placebo&#x02010;controlled study. Significant weight loss occurred with exenatide across <styled-content style="fixed-case">BMI</styled-content> range groups (p &#x0003c; 0.0001), while weight increased with both comparators. Achievement of <styled-content style="fixed-case">HbA1c</styled-content> &#x0003c;7.0% (&#x0003c;53 mmol/mol) without weight gain was greater for exenatide versus comparators. Systolic blood pressure decreased across <styled-content style="fixed-case">BMI</styled-content> range groups with exenatide in the lispro&#x02010;comparator study (p &#x0003c; 0.0001); changes in lipids were not clinically meaningful. Minor hypoglycaemia was less frequent for exenatide versus insulin lispro. These findings suggest that <styled-content style="fixed-case">BMI</styled-content> alone should not limit clinical decision&#x02010;making or patient access to medication.</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="dom12669-kwd-0001">body mass index</kwd><kwd id="dom12669-kwd-0002">exenatide twice daily</kwd><kwd id="dom12669-kwd-0003">type 2 diabetes</kwd></kwd-group><funding-group><award-group><funding-source>Eli Lilly and Company</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Amylin Pharmaceuticals</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Bristol&#x02010;Myers Squibb</funding-source></award-group></funding-group><funding-group><award-group><funding-source>AstraZeneca</funding-source></award-group></funding-group><counts><page-count count="5"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>dom12669</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>August 2016</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:4.9.7 mode:remove_FC converted:16.11.2016</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group><fn id="dom12669-note-0100"><p>[The copyright line for this article was changed on 6th June after original online publication.]</p></fn></fn-group></notes></front><body><sec id="dom12669-sec-0001"><title>Introduction</title><p id="dom12669-para-0004">Type 2 diabetes (T2D) is a progressive disease requiring stepwise treatment intensification to maintain glycaemic control <xref rid="dom12669-bib-0001" ref-type="ref">1</xref>. Recently, we reported that adding the short&#x02010;acting glucagon&#x02010;like peptide&#x02010;1 receptor agonist (GLP&#x02010;1RA) exenatide twice daily to basal insulin improved glycaemic control similarly to the addition of mealtime (three times daily) insulin lispro to basal insulin, but with less non&#x02010;nocturnal hypoglycaemia, weight loss, reduced systolic blood pressure (SBP) and improved quality of life <xref rid="dom12669-bib-0002" ref-type="ref">2</xref>. Additional studies have reported beneficial effects of the combination of a GLP&#x02010;1RA and insulin <xref rid="dom12669-bib-0003" ref-type="ref">3</xref>, <xref rid="dom12669-bib-0004" ref-type="ref">4</xref>. Accordingly, recent international guidelines have included the addition of a GLP&#x02010;1RA to background basal insulin as an option for patients requiring combination injectable treatments <xref rid="dom12669-bib-0001" ref-type="ref">1</xref>. However, several countries restrict reimbursement of GLP&#x02010;1RAs to only patients with a body mass index (BMI) &#x02265;35 kg/m<sup>2</sup>
<xref rid="dom12669-bib-0005" ref-type="ref">5</xref>, <xref rid="dom12669-bib-0006" ref-type="ref">6</xref>.</p><p id="dom12669-para-0005">In the present <italic>post hoc</italic> analysis, we assessed the evidence behind common reimbursement practices by evaluating the relationship of standard BMI ranges with the effects of exenatide twice daily among patients with T2D treated with insulin glargine in two 30&#x02010;week studies.</p></sec><sec id="dom12669-sec-0002"><title>Materials and Methods</title><sec id="dom12669-sec-0003"><title>Study Design and Patients</title><p id="dom12669-para-0006">This <italic>post hoc</italic> analysis included two open&#x02010;label, randomized, non&#x02010;inferiority studies that were published previously <xref rid="dom12669-bib-0002" ref-type="ref">2</xref>, <xref rid="dom12669-bib-0007" ref-type="ref">7</xref>. The lispro&#x02010;comparator study (NCT00960661) investigated the efficacy and safety of exenatide twice daily versus insulin lispro added to background insulin glargine and metformin, after a basal insulin optimization phase in which bedtime insulin glargine was titrated based on self&#x02010;monitored blood glucose. The placebo&#x02010;controlled study (NCT00765817) investigated the efficacy and safety of exenatide twice daily versus placebo when added to background insulin glargine, with or without metformin and/or pioglitazone. Detailed methods of both studies have been described previously <xref rid="dom12669-bib-0002" ref-type="ref">2</xref>, <xref rid="dom12669-bib-0007" ref-type="ref">7</xref>, and study procedures are shown in Figure S1, Supporting Information. The exenatide dose was 5 &#x000b5;g twice daily for the first 4 weeks and 10 &#x000b5;g twice daily thereafter, given before breakfast and dinner.</p><p id="dom12669-para-0007">The protocol for each study was approved by an institutional review board, and both studies were conducted in accordance with the principles described in the Declaration of Helsinki. All patients provided written informed consent.</p></sec><sec id="dom12669-sec-0004"><title>Statistical Analyses</title><p id="dom12669-para-0008">The primary objective was to compare the changes from baseline in efficacy and safety measures with add&#x02010;on exenatide twice daily versus insulin lispro or placebo for three groups with standard ranges of baseline BMI (&#x0003c;30, 30&#x02013;35 and &#x0003e;35 kg/m<sup>2</sup>) <xref rid="dom12669-bib-0008" ref-type="ref">8</xref>, <xref rid="dom12669-bib-0009" ref-type="ref">9</xref> in the intention&#x02010;to&#x02010;treat (ITT) population, defined as all randomized patients who received &#x02265;1 dose of study drug.</p><p id="dom12669-para-0009">Efficacy measures included glycated haemoglobin (HbA1c), fasting plasma glucose (FPG), body weight, blood pressure (BP), LDL cholesterol, HDL cholesterol, LDL cholesterol/HDL cholesterol ratio, total cholesterol, triglycerides, and achievement of HbA1c &#x0003c;7.0% (&#x0003c;53 mmol/mol) and HbA1c &#x0003c;7.0% with no weight gain. Changes in BP and lipids were determined for patients in each BMI range group who did not add new antihypertensive or lipid&#x02010;lowering medication, respectively. Safety measures included the incidence of treatment&#x02010;emergent adverse events (TEAEs) and minor and major hypoglycaemia.</p><p id="dom12669-para-0010">Baseline demographics, TEAEs, hypoglycaemia rates and goal achievement were summarized by descriptive statistics. Changes from baseline to endpoint in efficacy variables were evaluated with the last observation carried forward method and analysed with an analysis of covariance model, in which the baseline value of the dependent variable was adjusted as a covariate. The relationship of baseline BMI to the change from baseline to endpoint in efficacy variables was examined, and the Pearson correlation coefficients (<italic>r</italic>) were provided.</p></sec></sec><sec id="dom12669-sec-0005"><title>Results</title><sec id="dom12669-sec-0006"><title>Study Population</title><p id="dom12669-para-0011">A total of 627 of 637 randomized patients in the lispro&#x02010;comparator study and 259 of 261 randomized patients in the placebo&#x02010;controlled study received &#x02265;1 dose of study medication after randomization and were included in this analysis. Mean baseline HbA1c ranged from 8.1 to 8.6% (65 to 69 mmol/mol; Table <xref rid="dom12669-tbl-0001" ref-type="table-wrap">1</xref>).</p><table-wrap id="dom12669-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Baseline characteristics by baseline <styled-content style="fixed-case">BMI</styled-content> range group (intention&#x02010;to&#x02010;treat population).</p></caption><table frame="above" rules="groups"><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th style="border-bottom:solid 1px #000000" align="left" id="dom12669-ent-0001" valign="bottom" rowspan="1" colspan="1"/><th colspan="3" align="left" id="dom12669-ent-0002" valign="bottom" rowspan="1">Exenatide twice daily</th><th colspan="3" align="left" id="dom12669-ent-0003" valign="bottom" rowspan="1">Insulin lispro</th></tr><tr><th style="border-bottom:solid 1px #000000" align="left" valign="bottom" rowspan="1" colspan="1">Lispro&#x02010;comparator</th><th align="center" id="dom12669-ent-0004" valign="bottom" rowspan="1" colspan="1">&#x0003c;30 kg/m<sup>2</sup>
</th><th align="center" id="dom12669-ent-0005" valign="bottom" rowspan="1" colspan="1">30&#x02013;35 kg/m<sup>2</sup>
</th><th align="center" id="dom12669-ent-0006" valign="bottom" rowspan="1" colspan="1">&#x0003e;35 kg/m<sup>2</sup>
</th><th align="center" id="dom12669-ent-0007" valign="bottom" rowspan="1" colspan="1">&#x0003c;30 kg/m<sup>2</sup>
</th><th align="center" id="dom12669-ent-0008" valign="bottom" rowspan="1" colspan="1">30&#x02013;35 kg/m<sup>2</sup>
</th><th align="center" id="dom12669-ent-0009" valign="bottom" rowspan="1" colspan="1">&#x0003e;35 kg/m<sup>2</sup>
</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">study characteristics</th><th align="center" id="dom12669-ent-0010" valign="bottom" rowspan="1" colspan="1">n = 107</th><th align="center" id="dom12669-ent-0011" valign="bottom" rowspan="1" colspan="1">n = 120</th><th align="center" id="dom12669-ent-0012" valign="bottom" rowspan="1" colspan="1">n = 88</th><th align="center" id="dom12669-ent-0013" valign="bottom" rowspan="1" colspan="1">n = 113</th><th align="center" id="dom12669-ent-0014" valign="bottom" rowspan="1" colspan="1">n = 111</th><th align="center" id="dom12669-ent-0015" valign="bottom" rowspan="1" colspan="1">n = 88</th></tr></thead><tbody valign="top"><tr><td align="left" id="dom12669-ent-0016" valign="top" rowspan="1" colspan="1">Male, n (%)</td><td align="char" char="." id="dom12669-ent-0017" valign="top" rowspan="1" colspan="1">68 (63.6)</td><td align="char" char="." id="dom12669-ent-0018" valign="top" rowspan="1" colspan="1">52 (43.3)</td><td align="char" char="." id="dom12669-ent-0019" valign="top" rowspan="1" colspan="1">35 (39.8)</td><td align="char" char="." id="dom12669-ent-0020" valign="top" rowspan="1" colspan="1">55 (48.7)</td><td align="char" char="." id="dom12669-ent-0021" valign="top" rowspan="1" colspan="1">62 (55.9)</td><td align="char" char="." id="dom12669-ent-0022" valign="top" rowspan="1" colspan="1">41 (46.6)</td></tr><tr><td align="left" id="dom12669-ent-0023" valign="top" rowspan="1" colspan="1">Age, years</td><td align="char" char="." id="dom12669-ent-0024" valign="top" rowspan="1" colspan="1">61.8 (9.2)</td><td align="char" char="." id="dom12669-ent-0025" valign="top" rowspan="1" colspan="1">59.0 (10.2)</td><td align="char" char="." id="dom12669-ent-0026" valign="top" rowspan="1" colspan="1">59.1 (8.6)</td><td align="char" char="." id="dom12669-ent-0027" valign="top" rowspan="1" colspan="1">59.0 (9.5)</td><td align="char" char="." id="dom12669-ent-0028" valign="top" rowspan="1" colspan="1">60.8 (9.2)</td><td align="char" char="." id="dom12669-ent-0029" valign="top" rowspan="1" colspan="1">59.0 (9.7)</td></tr><tr><td align="left" id="dom12669-ent-0030" valign="top" rowspan="1" colspan="1">Body weight, kg</td><td align="char" char="." id="dom12669-ent-0031" valign="top" rowspan="1" colspan="1">77.0 (9.6)</td><td align="char" char="." id="dom12669-ent-0032" valign="top" rowspan="1" colspan="1">89.5 (11.5)</td><td align="char" char="." id="dom12669-ent-0033" valign="top" rowspan="1" colspan="1">106.1 (15.4)</td><td align="char" char="." id="dom12669-ent-0034" valign="top" rowspan="1" colspan="1">76.3 (10.6)</td><td align="char" char="." id="dom12669-ent-0035" valign="top" rowspan="1" colspan="1">90.0 (12.0)</td><td align="char" char="." id="dom12669-ent-0036" valign="top" rowspan="1" colspan="1">105.0 (16.5)</td></tr><tr><td align="left" id="dom12669-ent-0037" valign="top" rowspan="1" colspan="1">BMI, kg/m<sup>2</sup>
</td><td align="char" char="." id="dom12669-ent-0038" valign="top" rowspan="1" colspan="1">27.3 (1.7)</td><td align="char" char="." id="dom12669-ent-0039" valign="top" rowspan="1" colspan="1">32.4 (1.4)</td><td align="char" char="." id="dom12669-ent-0040" valign="top" rowspan="1" colspan="1">38.7 (2.5)</td><td align="char" char="." id="dom12669-ent-0041" valign="top" rowspan="1" colspan="1">27.6 (1.7)</td><td align="char" char="." id="dom12669-ent-0042" valign="top" rowspan="1" colspan="1">32.1 (1.3)</td><td align="char" char="." id="dom12669-ent-0043" valign="top" rowspan="1" colspan="1">38.4 (2.6)</td></tr><tr><td align="left" id="dom12669-ent-0044" valign="top" rowspan="1" colspan="1">HbA1c, mmol/mol</td><td align="char" char="." id="dom12669-ent-0045" valign="top" rowspan="1" colspan="1">65 (9.5)</td><td align="char" char="." id="dom12669-ent-0046" valign="top" rowspan="1" colspan="1">68 (11.1)</td><td align="char" char="." id="dom12669-ent-0047" valign="top" rowspan="1" colspan="1">68 (11.6)</td><td align="char" char="." id="dom12669-ent-0048" valign="top" rowspan="1" colspan="1">65 (9.1)</td><td align="char" char="." id="dom12669-ent-0049" valign="top" rowspan="1" colspan="1">66 (9.6)</td><td align="char" char="." id="dom12669-ent-0050" valign="top" rowspan="1" colspan="1">68 (10.1)</td></tr><tr><td align="left" id="dom12669-ent-0051" valign="top" rowspan="1" colspan="1">FPG, mmol/l</td><td align="char" char="." id="dom12669-ent-0052" valign="top" rowspan="1" colspan="1">6.4 (2.0)</td><td align="char" char="." id="dom12669-ent-0053" valign="top" rowspan="1" colspan="1">7.5 (2.6)</td><td align="char" char="." id="dom12669-ent-0054" valign="top" rowspan="1" colspan="1">7.5 (2.3)</td><td align="char" char="." id="dom12669-ent-0055" valign="top" rowspan="1" colspan="1">6.4 (2.3)</td><td align="char" char="." id="dom12669-ent-0056" valign="top" rowspan="1" colspan="1">7.4 (2.5)</td><td align="char" char="." id="dom12669-ent-0057" valign="top" rowspan="1" colspan="1">7.3 (2.7)</td></tr><tr><td align="left" id="dom12669-ent-0058" valign="top" rowspan="1" colspan="1">SBP, mmHg</td><td align="char" char="." id="dom12669-ent-0059" valign="top" rowspan="1" colspan="1">135.6 (14.5)</td><td align="char" char="." id="dom12669-ent-0060" valign="top" rowspan="1" colspan="1">136.6 (16.3)</td><td align="char" char="." id="dom12669-ent-0061" valign="top" rowspan="1" colspan="1">140.0 (16.3)</td><td align="char" char="." id="dom12669-ent-0062" valign="top" rowspan="1" colspan="1">130.9 (15.9)</td><td align="char" char="." id="dom12669-ent-0063" valign="top" rowspan="1" colspan="1">134.9 (15.1)</td><td align="char" char="." id="dom12669-ent-0064" valign="top" rowspan="1" colspan="1">137.9 (14.4)</td></tr><tr><td align="left" id="dom12669-ent-0065" valign="top" rowspan="1" colspan="1">DBP, mmHg</td><td align="char" char="." id="dom12669-ent-0066" valign="top" rowspan="1" colspan="1">75.9 (9.5)</td><td align="char" char="." id="dom12669-ent-0067" valign="top" rowspan="1" colspan="1">79.9 (8.5)</td><td align="char" char="." id="dom12669-ent-0068" valign="top" rowspan="1" colspan="1">81.7 (10.3)</td><td align="char" char="." id="dom12669-ent-0069" valign="top" rowspan="1" colspan="1">76.0 (9.3)</td><td align="char" char="." id="dom12669-ent-0070" valign="top" rowspan="1" colspan="1">78.4 (8.5)</td><td align="char" char="." id="dom12669-ent-0071" valign="top" rowspan="1" colspan="1">80.7 (9.2)</td></tr><tr><td align="left" id="dom12669-ent-0072" valign="top" rowspan="1" colspan="1">LDL cholesterol, mmol/l</td><td align="char" char="." id="dom12669-ent-0073" valign="top" rowspan="1" colspan="1">2.48 (0.92)</td><td align="char" char="." id="dom12669-ent-0074" valign="top" rowspan="1" colspan="1">2.53 (0.86)</td><td align="char" char="." id="dom12669-ent-0075" valign="top" rowspan="1" colspan="1">2.58 (0.83)</td><td align="char" char="." id="dom12669-ent-0076" valign="top" rowspan="1" colspan="1">2.63 (0.88)</td><td align="char" char="." id="dom12669-ent-0077" valign="top" rowspan="1" colspan="1">2.51 (0.89)</td><td align="char" char="." id="dom12669-ent-0078" valign="top" rowspan="1" colspan="1">2.66 (0.90)</td></tr><tr><td align="left" id="dom12669-ent-0079" valign="top" rowspan="1" colspan="1">HDL cholesterol, mmol/l</td><td align="char" char="." id="dom12669-ent-0080" valign="top" rowspan="1" colspan="1">1.29 (0.38)</td><td align="char" char="." id="dom12669-ent-0081" valign="top" rowspan="1" colspan="1">1.21 (0.32)</td><td align="char" char="." id="dom12669-ent-0082" valign="top" rowspan="1" colspan="1">1.19 (0.27)</td><td align="char" char="." id="dom12669-ent-0083" valign="top" rowspan="1" colspan="1">1.26 (0.32)</td><td align="char" char="." id="dom12669-ent-0084" valign="top" rowspan="1" colspan="1">1.14 (0.32)</td><td align="char" char="." id="dom12669-ent-0085" valign="top" rowspan="1" colspan="1">1.20 (0.31)</td></tr><tr><td align="left" id="dom12669-ent-0086" valign="top" rowspan="1" colspan="1">Total cholesterol, mmol/l</td><td align="char" char="." id="dom12669-ent-0087" valign="top" rowspan="1" colspan="1">4.55 (1.1)</td><td align="char" char="." id="dom12669-ent-0088" valign="top" rowspan="1" colspan="1">4.57 (1.0)</td><td align="char" char="." id="dom12669-ent-0089" valign="top" rowspan="1" colspan="1">4.61 (0.95)</td><td align="char" char="." id="dom12669-ent-0090" valign="top" rowspan="1" colspan="1">4.63 (0.99)</td><td align="char" char="." id="dom12669-ent-0091" valign="top" rowspan="1" colspan="1">4.48 (1.13)</td><td align="char" char="." id="dom12669-ent-0092" valign="top" rowspan="1" colspan="1">4.68 (0.99)</td></tr><tr><td align="left" id="dom12669-ent-0093" valign="top" rowspan="1" colspan="1">Triglycerides, mmol/l, median (range)</td><td align="char" char="." id="dom12669-ent-0094" valign="top" rowspan="1" colspan="1">1.49 (0.50, 5.97)</td><td align="char" char="." id="dom12669-ent-0095" valign="top" rowspan="1" colspan="1">1.59 (0.51, 9.13)</td><td align="char" char="." id="dom12669-ent-0096" valign="top" rowspan="1" colspan="1">1.65 (0.61, 7.57)</td><td align="char" char="." id="dom12669-ent-0097" valign="top" rowspan="1" colspan="1">1.45 (0.67, 5.54)</td><td align="char" char="." id="dom12669-ent-0098" valign="top" rowspan="1" colspan="1">1.48 (0.57, 8.64)</td><td align="char" char="." id="dom12669-ent-0099" valign="top" rowspan="1" colspan="1">1.60 (0.60, 5.73)</td></tr></tbody></table><table frame="above" rules="groups"><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th style="border-bottom:solid 1px #000000" align="left" id="dom12669-ent-0100" valign="bottom" rowspan="1" colspan="1"/><th colspan="3" align="left" id="dom12669-ent-0101" valign="bottom" rowspan="1">Exenatide twice daily</th><th colspan="3" align="left" id="dom12669-ent-0102" valign="bottom" rowspan="1">Placebo</th></tr><tr><th style="border-bottom:solid 1px #000000" align="left" valign="bottom" rowspan="1" colspan="1">Placebo&#x02010;controlled</th><th align="center" id="dom12669-ent-0103" valign="bottom" rowspan="1" colspan="1">&#x0003c;30 kg/m<sup>2</sup>
</th><th align="center" id="dom12669-ent-0104" valign="bottom" rowspan="1" colspan="1">30&#x02013;35 kg/m<sup>2</sup>
</th><th align="center" id="dom12669-ent-0105" valign="bottom" rowspan="1" colspan="1">&#x0003e;35 kg/m<sup>2</sup>
</th><th align="center" id="dom12669-ent-0106" valign="bottom" rowspan="1" colspan="1">&#x0003c;30 kg/m<sup>2</sup>
</th><th align="center" id="dom12669-ent-0107" valign="bottom" rowspan="1" colspan="1">30&#x02013;35 kg/m<sup>2</sup>
</th><th align="center" id="dom12669-ent-0108" valign="bottom" rowspan="1" colspan="1">&#x0003e;35 kg/m<sup>2</sup>
</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">study characteristics</th><th align="center" id="dom12669-ent-0109" valign="bottom" rowspan="1" colspan="1">n = 36</th><th align="center" id="dom12669-ent-0110" valign="bottom" rowspan="1" colspan="1">n = 50</th><th align="center" id="dom12669-ent-0111" valign="bottom" rowspan="1" colspan="1">n = 51</th><th align="center" id="dom12669-ent-0112" valign="bottom" rowspan="1" colspan="1">n = 43</th><th align="center" id="dom12669-ent-0113" valign="bottom" rowspan="1" colspan="1">n = 35</th><th align="center" id="dom12669-ent-0114" valign="bottom" rowspan="1" colspan="1">n = 44</th></tr></thead><tbody valign="top"><tr><td align="left" id="dom12669-ent-0115" valign="top" rowspan="1" colspan="1">Male, n (%)</td><td align="char" char="." id="dom12669-ent-0116" valign="top" rowspan="1" colspan="1">19 (52.8)</td><td align="char" char="." id="dom12669-ent-0117" valign="top" rowspan="1" colspan="1">32 (64.0)</td><td align="char" char="." id="dom12669-ent-0118" valign="top" rowspan="1" colspan="1">19 (37.3)</td><td align="char" char="." id="dom12669-ent-0119" valign="top" rowspan="1" colspan="1">32 (74.4)</td><td align="char" char="." id="dom12669-ent-0120" valign="top" rowspan="1" colspan="1">22 (62.9)</td><td align="char" char="." id="dom12669-ent-0121" valign="top" rowspan="1" colspan="1">24 (54.5)</td></tr><tr><td align="left" id="dom12669-ent-0122" valign="top" rowspan="1" colspan="1">Age, years</td><td align="char" char="." id="dom12669-ent-0123" valign="top" rowspan="1" colspan="1">62.2 (8.7)</td><td align="char" char="." id="dom12669-ent-0124" valign="top" rowspan="1" colspan="1">57.7 (9.5)</td><td align="char" char="." id="dom12669-ent-0125" valign="top" rowspan="1" colspan="1">55.5 (7.5)</td><td align="char" char="." id="dom12669-ent-0126" valign="top" rowspan="1" colspan="1">60.3 (12.0)</td><td align="char" char="." id="dom12669-ent-0127" valign="top" rowspan="1" colspan="1">59.5 (7.7)</td><td align="char" char="." id="dom12669-ent-0128" valign="top" rowspan="1" colspan="1">56.7 (9.1)</td></tr><tr><td align="left" id="dom12669-ent-0129" valign="top" rowspan="1" colspan="1">Body weight, kg</td><td align="char" char="." id="dom12669-ent-0130" valign="top" rowspan="1" colspan="1">73.7 (12.8)</td><td align="char" char="." id="dom12669-ent-0131" valign="top" rowspan="1" colspan="1">94.6 (11.4)</td><td align="char" char="." id="dom12669-ent-0132" valign="top" rowspan="1" colspan="1">111.4 (17.1)</td><td align="char" char="." id="dom12669-ent-0133" valign="top" rowspan="1" colspan="1">75.6 (12.8)</td><td align="char" char="." id="dom12669-ent-0134" valign="top" rowspan="1" colspan="1">89.7 (11.3)</td><td align="char" char="." id="dom12669-ent-0135" valign="top" rowspan="1" colspan="1">113.4 (16.2)</td></tr><tr><td align="left" id="dom12669-ent-0136" valign="top" rowspan="1" colspan="1">BMI, kg/m<sup>2</sup>
</td><td align="char" char="." id="dom12669-ent-0137" valign="top" rowspan="1" colspan="1">26.8 (2.6)</td><td align="char" char="." id="dom12669-ent-0138" valign="top" rowspan="1" colspan="1">32.7 (1.4)</td><td align="char" char="." id="dom12669-ent-0139" valign="top" rowspan="1" colspan="1">39.9 (3.2)</td><td align="char" char="." id="dom12669-ent-0140" valign="top" rowspan="1" colspan="1">26.9 (2.6)</td><td align="char" char="." id="dom12669-ent-0141" valign="top" rowspan="1" colspan="1">32.3 (1.3)</td><td align="char" char="." id="dom12669-ent-0142" valign="top" rowspan="1" colspan="1">39.7 (3.9)</td></tr><tr><td align="left" id="dom12669-ent-0143" valign="top" rowspan="1" colspan="1">HbA1c, mmol/mol</td><td align="char" char="." id="dom12669-ent-0144" valign="top" rowspan="1" colspan="1">67 (8.0)</td><td align="char" char="." id="dom12669-ent-0145" valign="top" rowspan="1" colspan="1">66 (8.6)</td><td align="char" char="." id="dom12669-ent-0146" valign="top" rowspan="1" colspan="1">69 (10.5)</td><td align="char" char="." id="dom12669-ent-0147" valign="top" rowspan="1" colspan="1">69 (11.0)</td><td align="char" char="." id="dom12669-ent-0148" valign="top" rowspan="1" colspan="1">70 (10.5)</td><td align="char" char="." id="dom12669-ent-0149" valign="top" rowspan="1" colspan="1">70 (10.2)</td></tr><tr><td align="left" id="dom12669-ent-0150" valign="top" rowspan="1" colspan="1">FPG, mmol/l</td><td align="char" char="." id="dom12669-ent-0151" valign="top" rowspan="1" colspan="1">7.2 (2.8)</td><td align="char" char="." id="dom12669-ent-0152" valign="top" rowspan="1" colspan="1">7.2 (2.1)</td><td align="char" char="." id="dom12669-ent-0153" valign="top" rowspan="1" colspan="1">7.5 (2.8)</td><td align="char" char="." id="dom12669-ent-0154" valign="top" rowspan="1" colspan="1">6.6 (2.2)</td><td align="char" char="." id="dom12669-ent-0155" valign="top" rowspan="1" colspan="1">7.8 (3.3)</td><td align="char" char="." id="dom12669-ent-0156" valign="top" rowspan="1" colspan="1">8.0 (2.4)</td></tr><tr><td align="left" id="dom12669-ent-0157" valign="top" rowspan="1" colspan="1">SBP, mmHg</td><td align="char" char="." id="dom12669-ent-0158" valign="top" rowspan="1" colspan="1">129.8 (15.0)</td><td align="char" char="." id="dom12669-ent-0159" valign="top" rowspan="1" colspan="1">128.4 (15.5)</td><td align="char" char="." id="dom12669-ent-0160" valign="top" rowspan="1" colspan="1">131.4 (17.4)</td><td align="char" char="." id="dom12669-ent-0161" valign="top" rowspan="1" colspan="1">126.4 (12.3)</td><td align="char" char="." id="dom12669-ent-0162" valign="top" rowspan="1" colspan="1">126.6 (13.7)</td><td align="char" char="." id="dom12669-ent-0163" valign="top" rowspan="1" colspan="1">129.5 (15.1)</td></tr><tr><td align="left" id="dom12669-ent-0164" valign="top" rowspan="1" colspan="1">DBP, mmHg</td><td align="char" char="." id="dom12669-ent-0165" valign="top" rowspan="1" colspan="1">71.5 (8.1)</td><td align="char" char="." id="dom12669-ent-0166" valign="top" rowspan="1" colspan="1">75.5 (8.5)</td><td align="char" char="." id="dom12669-ent-0167" valign="top" rowspan="1" colspan="1">79.0 (10.7)</td><td align="char" char="." id="dom12669-ent-0168" valign="top" rowspan="1" colspan="1">72.7 (7.9)</td><td align="char" char="." id="dom12669-ent-0169" valign="top" rowspan="1" colspan="1">74.0 (10.6)</td><td align="char" char="." id="dom12669-ent-0170" valign="top" rowspan="1" colspan="1">76.2 (7.9)</td></tr><tr><td align="left" id="dom12669-ent-0171" valign="top" rowspan="1" colspan="1">LDL cholesterol, mmol/l</td><td align="char" char="." id="dom12669-ent-0172" valign="top" rowspan="1" colspan="1">2.61 (0.95)</td><td align="char" char="." id="dom12669-ent-0173" valign="top" rowspan="1" colspan="1">2.32 (0.93)</td><td align="char" char="." id="dom12669-ent-0174" valign="top" rowspan="1" colspan="1">2.55 (0.92)</td><td align="char" char="." id="dom12669-ent-0175" valign="top" rowspan="1" colspan="1">2.31 (0.69)</td><td align="char" char="." id="dom12669-ent-0176" valign="top" rowspan="1" colspan="1">2.43 (0.83)</td><td align="char" char="." id="dom12669-ent-0177" valign="top" rowspan="1" colspan="1">2.55 (1.05)</td></tr><tr><td align="left" id="dom12669-ent-0178" valign="top" rowspan="1" colspan="1">HDL cholesterol, mmol/l</td><td align="char" char="." id="dom12669-ent-0179" valign="top" rowspan="1" colspan="1">1.20 (0.30)</td><td align="char" char="." id="dom12669-ent-0180" valign="top" rowspan="1" colspan="1">1.12 (0.29)</td><td align="char" char="." id="dom12669-ent-0181" valign="top" rowspan="1" colspan="1">1.13 (0.24)</td><td align="char" char="." id="dom12669-ent-0182" valign="top" rowspan="1" colspan="1">1.19 (0.31)</td><td align="char" char="." id="dom12669-ent-0183" valign="top" rowspan="1" colspan="1">1.13 (0.29)</td><td align="char" char="." id="dom12669-ent-0184" valign="top" rowspan="1" colspan="1">1.09 (0.30)</td></tr><tr><td align="left" id="dom12669-ent-0185" valign="top" rowspan="1" colspan="1">Total cholesterol, mmol/l</td><td align="char" char="." id="dom12669-ent-0186" valign="top" rowspan="1" colspan="1">4.57 (1.10)</td><td align="char" char="." id="dom12669-ent-0187" valign="top" rowspan="1" colspan="1">4.22 (1.07)</td><td align="char" char="." id="dom12669-ent-0188" valign="top" rowspan="1" colspan="1">4.55 (1.09)</td><td align="char" char="." id="dom12669-ent-0189" valign="top" rowspan="1" colspan="1">4.12 (0.88)</td><td align="char" char="." id="dom12669-ent-0190" valign="top" rowspan="1" colspan="1">4.34 (0.90)</td><td align="char" char="." id="dom12669-ent-0191" valign="top" rowspan="1" colspan="1">4.43 (1.17)</td></tr><tr><td align="left" id="dom12669-ent-0192" valign="top" rowspan="1" colspan="1">Triglycerides, mmol/l, median (range)</td><td align="char" char="." id="dom12669-ent-0193" valign="top" rowspan="1" colspan="1">1.40 (0.45, 5.68)</td><td align="char" char="." id="dom12669-ent-0194" valign="top" rowspan="1" colspan="1">1.49 (0.59, 5.31)</td><td align="char" char="." id="dom12669-ent-0195" valign="top" rowspan="1" colspan="1">1.83 (0.45, 5.57)</td><td align="char" char="." id="dom12669-ent-0196" valign="top" rowspan="1" colspan="1">1.27 (0.46, 3.79)</td><td align="char" char="." id="dom12669-ent-0197" valign="top" rowspan="1" colspan="1">1.50 (0.73, 4.03)</td><td align="char" char="." id="dom12669-ent-0198" valign="top" rowspan="1" colspan="1">1.46 (0.80, 3.63)</td></tr></tbody></table><table-wrap-foot><fn id="dom12669-note-0001"><p>Data are mean (standard deviation) unless otherwise stated. <styled-content style="fixed-case">BMI</styled-content>, body mass index; <styled-content style="fixed-case">DBP</styled-content>, diastolic blood pressure; <styled-content style="fixed-case">FPG</styled-content>, fasting plasma glucose; <styled-content style="fixed-case">HbA1c</styled-content>, glycated haemoglobin; <styled-content style="fixed-case">SBP</styled-content>, systolic blood pressure.</p></fn></table-wrap-foot></table-wrap></sec><sec id="dom12669-sec-0007"><title>Efficacy Measures</title><p id="dom12669-para-0012">HbA1c was significantly reduced from baseline among all groups (p &#x0003c; 0.001; Table <xref rid="dom12669-tbl-0002" ref-type="table-wrap">2</xref>). FPG reductions were numerically greater for exenatide twice daily versus comparator in both studies in all BMI range groups except BMI &#x0003c;30 kg/m<sup>2</sup> in the placebo&#x02010;controlled study. Baseline BMI was not correlated with changes from baseline in HbA1c (range of <italic>r</italic>&#x02010;values, &#x02212;0.05 to &#x02212;0.15) or FPG (range of <italic>r</italic>&#x02010;values, &#x02212;0.04 to &#x02212;0.13) for any treatment group in either study. Achievement of HbA1c &#x0003c;7.0% (&#x0003c;53 mmol/mol) was numerically higher for patients receiving add&#x02010;on exenatide twice daily versus comparator in all groups except for the BMI 30&#x02013;35 kg/m<sup>2</sup> group in the lispro&#x02010;comparator study (Table <xref rid="dom12669-tbl-0002" ref-type="table-wrap">2</xref>).</p><table-wrap id="dom12669-tbl-0002" xml:lang="en" orientation="portrait" position="float"><label>Table 2</label><caption><p>Metabolic and cardiovascular characteristics in the intention&#x02010;to&#x02010;treat population.</p></caption><table frame="above" rules="groups"><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th rowspan="2" valign="bottom" align="left" id="dom12669-ent-0202" colspan="1">Lispro&#x02010;comparator study</th><th colspan="3" align="left" id="dom12669-ent-0200" valign="bottom" rowspan="1">Exenatide twice daily</th><th colspan="3" align="left" id="dom12669-ent-0201" valign="bottom" rowspan="1">Insulin lispro</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" id="dom12669-ent-0203" valign="bottom" rowspan="1" colspan="1">BMI &#x0003c;30 kg/m<sup>2</sup> n = 107</th><th align="left" id="dom12669-ent-0204" valign="bottom" rowspan="1" colspan="1">BMI 30&#x02013;35 kg/m<sup>2</sup> n = 120</th><th align="left" id="dom12669-ent-0205" valign="bottom" rowspan="1" colspan="1">BMI &#x0003e;35 kg/m<sup>2</sup> n = 88</th><th align="left" id="dom12669-ent-0206" valign="bottom" rowspan="1" colspan="1">BMI &#x0003c;30 kg/m<sup>2</sup> n = 113</th><th align="left" id="dom12669-ent-0207" valign="bottom" rowspan="1" colspan="1">BMI 30&#x02013;35 kg/m<sup>2</sup> n = 111</th><th align="left" id="dom12669-ent-0208" valign="bottom" rowspan="1" colspan="1">BMI &#x0003e;35 kg/m<sup>2</sup> n = 88</th></tr></thead><tbody valign="top"><tr><td colspan="7" align="left" id="dom12669-ent-0209" valign="top" rowspan="1">Change from baseline</td></tr><tr><td style="padding-left:10%" align="left" id="dom12669-ent-0210" valign="top" rowspan="1" colspan="1">HbA1c, mmol/mol</td><td align="left" id="dom12669-ent-0211" valign="top" rowspan="1" colspan="1">&#x02212;10.7 (1.0)<xref ref-type="fn" rid="dom12669-note-0003">*</xref>
</td><td align="left" id="dom12669-ent-0212" valign="top" rowspan="1" colspan="1">&#x02212;10.9 (0.8)<xref ref-type="fn" rid="dom12669-note-0003">*</xref>
</td><td align="left" id="dom12669-ent-0213" valign="top" rowspan="1" colspan="1">&#x02212;11.9 (1.2)<xref ref-type="fn" rid="dom12669-note-0003">*</xref>
</td><td align="left" id="dom12669-ent-0214" valign="top" rowspan="1" colspan="1">&#x02212;9.6 (0.9)<xref ref-type="fn" rid="dom12669-note-0003">*</xref>
</td><td align="left" id="dom12669-ent-0215" valign="top" rowspan="1" colspan="1">&#x02212;11.0 (0.9)<xref ref-type="fn" rid="dom12669-note-0003">*</xref>
</td><td align="left" id="dom12669-ent-0216" valign="top" rowspan="1" colspan="1">&#x02212;12.4 (1.0)<xref ref-type="fn" rid="dom12669-note-0003">*</xref>
</td></tr><tr><td align="left" style="padding-left:10%" id="dom12669-ent-0217" valign="top" rowspan="1" colspan="1">FPG, mmol/l</td><td align="left" id="dom12669-ent-0218" valign="top" rowspan="1" colspan="1">&#x02212;0.22 (0.26)</td><td align="left" id="dom12669-ent-0219" valign="top" rowspan="1" colspan="1">&#x02212;0.65 (0.27)<xref ref-type="fn" rid="dom12669-note-0003">*</xref>
</td><td align="left" id="dom12669-ent-0220" valign="top" rowspan="1" colspan="1">&#x02212;0.62 (0.33)</td><td align="left" id="dom12669-ent-0221" valign="top" rowspan="1" colspan="1">0.67 (0.28)<xref ref-type="fn" rid="dom12669-note-0003">*</xref>
</td><td align="left" id="dom12669-ent-0222" valign="top" rowspan="1" colspan="1">0.22 (0.32)</td><td align="left" id="dom12669-ent-0223" valign="top" rowspan="1" colspan="1">&#x02212;0.16 (0.34)</td></tr><tr><td align="left" style="padding-left:10%" id="dom12669-ent-0224" valign="top" rowspan="1" colspan="1">Body weight, kg</td><td align="left" id="dom12669-ent-0225" valign="top" rowspan="1" colspan="1">&#x02212;2.1 (0.3)<xref ref-type="fn" rid="dom12669-note-0003">*</xref>
</td><td align="left" id="dom12669-ent-0226" valign="top" rowspan="1" colspan="1">&#x02212;2.0 (0.3)<xref ref-type="fn" rid="dom12669-note-0003">*</xref>
</td><td align="left" id="dom12669-ent-0227" valign="top" rowspan="1" colspan="1">&#x02212;3.6 (0.6)<xref ref-type="fn" rid="dom12669-note-0003">*</xref>
</td><td align="left" id="dom12669-ent-0228" valign="top" rowspan="1" colspan="1">1.8 (0.3)<xref ref-type="fn" rid="dom12669-note-0003">*</xref>
</td><td align="left" id="dom12669-ent-0229" valign="top" rowspan="1" colspan="1">1.5 (0.3)<xref ref-type="fn" rid="dom12669-note-0003">*</xref>
</td><td align="left" id="dom12669-ent-0230" valign="top" rowspan="1" colspan="1">2.3 (0.5)<xref ref-type="fn" rid="dom12669-note-0003">*</xref>
</td></tr><tr><td align="left" style="padding-left:10%" id="dom12669-ent-0231" valign="top" rowspan="1" colspan="1">SBP, mmHg</td><td align="left" id="dom12669-ent-0232" valign="top" rowspan="1" colspan="1">&#x02212;4.3 (1.5)<xref ref-type="fn" rid="dom12669-note-0003">*</xref>
</td><td align="left" id="dom12669-ent-0233" valign="top" rowspan="1" colspan="1">&#x02212;4.0 (1.4)<xref ref-type="fn" rid="dom12669-note-0003">*</xref>
</td><td align="left" id="dom12669-ent-0234" valign="top" rowspan="1" colspan="1">&#x02212;5.3 (1.7)<xref ref-type="fn" rid="dom12669-note-0003">*</xref>
</td><td align="left" id="dom12669-ent-0235" valign="top" rowspan="1" colspan="1">2.1 (1.6)</td><td align="left" id="dom12669-ent-0236" valign="top" rowspan="1" colspan="1">1.8 (1.3)</td><td align="left" id="dom12669-ent-0237" valign="top" rowspan="1" colspan="1">&#x02212;1.4 (1.8)</td></tr><tr><td align="left" style="padding-left:10%" id="dom12669-ent-0238" valign="top" rowspan="1" colspan="1">DBP, mmHg</td><td align="left" id="dom12669-ent-0239" valign="top" rowspan="1" colspan="1">&#x02212;0.2 (0.9)</td><td align="left" id="dom12669-ent-0240" valign="top" rowspan="1" colspan="1">&#x02212;1.1 (0.8)</td><td align="left" id="dom12669-ent-0241" valign="top" rowspan="1" colspan="1">&#x02212;1.9 (1.2)</td><td align="left" id="dom12669-ent-0242" valign="top" rowspan="1" colspan="1">1.3 (1.0)</td><td align="left" id="dom12669-ent-0243" valign="top" rowspan="1" colspan="1">0.6 (0.8)</td><td align="left" id="dom12669-ent-0244" valign="top" rowspan="1" colspan="1">&#x02212;1.7 (1.0)</td></tr><tr><td align="left" style="padding-left:10%" id="dom12669-ent-0245" valign="top" rowspan="1" colspan="1">LDL cholesterol, mmol/l</td><td align="left" id="dom12669-ent-0246" valign="top" rowspan="1" colspan="1">&#x02212;0.01 (0.07)</td><td align="left" id="dom12669-ent-0247" valign="top" rowspan="1" colspan="1">&#x02212;0.11 (0.05)<xref ref-type="fn" rid="dom12669-note-0003">*</xref>
</td><td align="left" id="dom12669-ent-0248" valign="top" rowspan="1" colspan="1">&#x02212;0.16 (0.07)<xref ref-type="fn" rid="dom12669-note-0003">*</xref>
</td><td align="left" id="dom12669-ent-0249" valign="top" rowspan="1" colspan="1">0.05 (0.06)</td><td align="left" id="dom12669-ent-0250" valign="top" rowspan="1" colspan="1">&#x02212;0.01 (0.06)</td><td align="left" id="dom12669-ent-0251" valign="top" rowspan="1" colspan="1">&#x02212;0.13 (0.08)</td></tr><tr><td align="left" style="padding-left:10%" id="dom12669-ent-0252" valign="top" rowspan="1" colspan="1">HDL cholesterol, mmol/l</td><td align="left" id="dom12669-ent-0253" valign="top" rowspan="1" colspan="1">&#x02212;0.05 (0.02)<xref ref-type="fn" rid="dom12669-note-0003">*</xref>
</td><td align="left" id="dom12669-ent-0254" valign="top" rowspan="1" colspan="1">&#x02212;0.04 (0.02)<xref ref-type="fn" rid="dom12669-note-0003">*</xref>
</td><td align="left" id="dom12669-ent-0255" valign="top" rowspan="1" colspan="1">&#x02212;0.01 (0.02)</td><td align="left" id="dom12669-ent-0256" valign="top" rowspan="1" colspan="1">0.03 (0.02)</td><td align="left" id="dom12669-ent-0257" valign="top" rowspan="1" colspan="1">0.05 (0.02)<xref ref-type="fn" rid="dom12669-note-0003">*</xref>
</td><td align="left" id="dom12669-ent-0258" valign="top" rowspan="1" colspan="1">0.03 (0.02)</td></tr><tr><td align="left" style="padding-left:10%" id="dom12669-ent-0259" valign="top" rowspan="1" colspan="1">LDL cholesterol/HDL cholesterol ratio, mmol/l</td><td align="left" id="dom12669-ent-0260" valign="top" rowspan="1" colspan="1">0.07 (0.06)</td><td align="left" id="dom12669-ent-0261" valign="top" rowspan="1" colspan="1">&#x02212;0.04 (0.05)</td><td align="left" id="dom12669-ent-0262" valign="top" rowspan="1" colspan="1">&#x02212;0.13 (0.06)<xref ref-type="fn" rid="dom12669-note-0003">*</xref>
</td><td align="left" id="dom12669-ent-0263" valign="top" rowspan="1" colspan="1">0.01 (0.06)</td><td align="left" id="dom12669-ent-0264" valign="top" rowspan="1" colspan="1">&#x02212;0.09 (0.06)</td><td align="left" id="dom12669-ent-0265" valign="top" rowspan="1" colspan="1">&#x02212;0.15 (0.07)<xref ref-type="fn" rid="dom12669-note-0003">*</xref>
</td></tr><tr><td align="left" style="padding-left:10%" id="dom12669-ent-0266" valign="top" rowspan="1" colspan="1">Total cholesterol, mmol/l</td><td align="left" id="dom12669-ent-0267" valign="top" rowspan="1" colspan="1">&#x02212;0.09 (0.08)</td><td align="left" id="dom12669-ent-0268" valign="top" rowspan="1" colspan="1">&#x02212;0.1 (0.06)</td><td align="left" id="dom12669-ent-0269" valign="top" rowspan="1" colspan="1">&#x02212;0.16 (0.09)</td><td align="left" id="dom12669-ent-0270" valign="top" rowspan="1" colspan="1">0.09 (0.08)</td><td align="left" id="dom12669-ent-0271" valign="top" rowspan="1" colspan="1">0.05 (0.07)</td><td align="left" id="dom12669-ent-0272" valign="top" rowspan="1" colspan="1">&#x02212;0.12 (0.09)</td></tr><tr><td align="left" style="padding-left:10%" id="dom12669-ent-0273" valign="top" rowspan="1" colspan="1">Triglycerides, mmol/l, median</td><td align="left" id="dom12669-ent-0274" valign="top" rowspan="1" colspan="1">&#x02212;0.07</td><td align="left" id="dom12669-ent-0275" valign="top" rowspan="1" colspan="1">0.12</td><td align="left" id="dom12669-ent-0276" valign="top" rowspan="1" colspan="1">0.03</td><td align="left" id="dom12669-ent-0277" valign="top" rowspan="1" colspan="1">0.01</td><td align="left" id="dom12669-ent-0278" valign="top" rowspan="1" colspan="1">&#x02212;0.05</td><td align="left" id="dom12669-ent-0279" valign="top" rowspan="1" colspan="1">&#x02212;0.06</td></tr><tr><td align="left" id="dom12669-ent-0280" valign="top" rowspan="1" colspan="1">Patients achieving HbA1c &#x0003c;7.0% (&#x0003c;53 mmol/mol) at endpoint, n (%)</td><td align="left" id="dom12669-ent-0281" valign="top" rowspan="1" colspan="1">56 (52.3)</td><td align="left" id="dom12669-ent-0282" valign="top" rowspan="1" colspan="1">42 (35.0)</td><td align="left" id="dom12669-ent-0283" valign="top" rowspan="1" colspan="1">36 (40.9)</td><td align="left" id="dom12669-ent-0284" valign="top" rowspan="1" colspan="1">46 (40.7)</td><td align="left" id="dom12669-ent-0285" valign="top" rowspan="1" colspan="1">51 (45.9)</td><td align="left" id="dom12669-ent-0286" valign="top" rowspan="1" colspan="1">28 (31.8)</td></tr><tr><td align="left" id="dom12669-ent-0287" valign="top" rowspan="1" colspan="1">Patients achieving HbA1c &#x0003c;7.0% (&#x0003c;53 mmol/mol) and no weight gain at endpoint, n (%)</td><td align="left" id="dom12669-ent-0288" valign="top" rowspan="1" colspan="1">51 (47.7)</td><td align="left" id="dom12669-ent-0289" valign="top" rowspan="1" colspan="1">31 (25.8)</td><td align="left" id="dom12669-ent-0290" valign="top" rowspan="1" colspan="1">33 (37.5)</td><td align="left" id="dom12669-ent-0291" valign="top" rowspan="1" colspan="1">16 (14.2)</td><td align="left" id="dom12669-ent-0292" valign="top" rowspan="1" colspan="1">21 (18.9)</td><td align="left" id="dom12669-ent-0293" valign="top" rowspan="1" colspan="1">10 (11.4)</td></tr></tbody></table><table frame="above" rules="groups"><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th rowspan="2" valign="bottom" align="left" id="dom12669-ent-0297" colspan="1">Placebo&#x02010;controlled study</th><th colspan="3" align="left" id="dom12669-ent-0295" valign="bottom" rowspan="1">Exenatide twice daily</th><th colspan="3" align="left" id="dom12669-ent-0296" valign="bottom" rowspan="1">Placebo</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" id="dom12669-ent-0298" valign="bottom" rowspan="1" colspan="1">BMI &#x0003c;30 kg/m<sup>2</sup> n = 36</th><th align="left" id="dom12669-ent-0299" valign="bottom" rowspan="1" colspan="1">BMI 30&#x02013;35 kg/m<sup>2</sup> n = 50</th><th align="left" id="dom12669-ent-0300" valign="bottom" rowspan="1" colspan="1">BMI &#x0003e;35 kg/m<sup>2</sup> n = 51</th><th align="left" id="dom12669-ent-0301" valign="bottom" rowspan="1" colspan="1">BMI &#x0003c;30 kg/m<sup>2</sup> n = 43</th><th align="left" id="dom12669-ent-0302" valign="bottom" rowspan="1" colspan="1">BMI 30&#x02013;35 kg/m<sup>2</sup> n = 35</th><th align="left" id="dom12669-ent-0303" valign="bottom" rowspan="1" colspan="1">BMI &#x0003e;35 kg/m<sup>2</sup> n = 44</th></tr></thead><tbody valign="top"><tr><td colspan="7" align="left" id="dom12669-ent-0304" valign="top" rowspan="1">Change from baseline</td></tr><tr><td align="left" style="padding-left:10%" id="dom12669-ent-0305" valign="top" rowspan="1" colspan="1">HbA1c, mmol/mol</td><td align="left" id="dom12669-ent-0306" valign="top" rowspan="1" colspan="1">&#x02212;12.5 (2.0)<xref ref-type="fn" rid="dom12669-note-0003">*</xref>
</td><td align="left" id="dom12669-ent-0307" valign="top" rowspan="1" colspan="1">&#x02212;16.5 (1.6)<xref ref-type="fn" rid="dom12669-note-0003">*</xref>
</td><td align="left" id="dom12669-ent-0308" valign="top" rowspan="1" colspan="1">&#x02212;16.5 (1.4)<xref ref-type="fn" rid="dom12669-note-0003">*</xref>
</td><td align="left" id="dom12669-ent-0309" valign="top" rowspan="1" colspan="1">&#x02212;9.6 (1.6)<xref ref-type="fn" rid="dom12669-note-0003">*</xref>
</td><td align="left" id="dom12669-ent-0310" valign="top" rowspan="1" colspan="1">&#x02212;9.8 (2.1)<xref ref-type="fn" rid="dom12669-note-0003">*</xref>
</td><td align="left" id="dom12669-ent-0311" valign="top" rowspan="1" colspan="1">&#x02212;11.9 (1.5)<xref ref-type="fn" rid="dom12669-note-0003">*</xref>
</td></tr><tr><td align="left" style="padding-left:10%" id="dom12669-ent-0312" valign="top" rowspan="1" colspan="1">FPG, mmol/l</td><td align="left" id="dom12669-ent-0313" valign="top" rowspan="1" colspan="1">&#x02212;0.32 (0.65)</td><td align="left" id="dom12669-ent-0314" valign="top" rowspan="1" colspan="1">&#x02212;1.45 (0.39)<xref ref-type="fn" rid="dom12669-note-0003">*</xref>
</td><td align="left" id="dom12669-ent-0315" valign="top" rowspan="1" colspan="1">&#x02212;1.06 (0.49)<xref ref-type="fn" rid="dom12669-note-0003">*</xref>
</td><td align="left" id="dom12669-ent-0316" valign="top" rowspan="1" colspan="1">&#x02212;0.53 (0.45)</td><td align="left" id="dom12669-ent-0317" valign="top" rowspan="1" colspan="1">&#x02212;0.77 (0.72)</td><td align="left" id="dom12669-ent-0318" valign="top" rowspan="1" colspan="1">&#x02212;0.94 (0.65)</td></tr><tr><td align="left" style="padding-left:10%" id="dom12669-ent-0319" valign="top" rowspan="1" colspan="1">Body weight, kg</td><td align="left" id="dom12669-ent-0320" valign="top" rowspan="1" colspan="1">&#x02212;0.4 (0.4)</td><td align="left" id="dom12669-ent-0321" valign="top" rowspan="1" colspan="1">&#x02212;2.6 (0.6)<xref ref-type="fn" rid="dom12669-note-0003">*</xref>
</td><td align="left" id="dom12669-ent-0322" valign="top" rowspan="1" colspan="1">&#x02212;1.5 (0.6)<xref ref-type="fn" rid="dom12669-note-0003">*</xref>
</td><td align="left" id="dom12669-ent-0323" valign="top" rowspan="1" colspan="1">1.2 (0.4)<xref ref-type="fn" rid="dom12669-note-0003">*</xref>
</td><td align="left" id="dom12669-ent-0324" valign="top" rowspan="1" colspan="1">&#x02212;0 (0.6)</td><td align="left" id="dom12669-ent-0325" valign="top" rowspan="1" colspan="1">1.2 (0.6)<xref ref-type="fn" rid="dom12669-note-0003">*</xref>
</td></tr><tr><td align="left" style="padding-left:10%" id="dom12669-ent-0326" valign="top" rowspan="1" colspan="1">SBP, mmHg</td><td align="left" id="dom12669-ent-0327" valign="top" rowspan="1" colspan="1">&#x02212;3.6 (2.5)</td><td align="left" id="dom12669-ent-0328" valign="top" rowspan="1" colspan="1">&#x02212;2.8 (2.3)</td><td align="left" id="dom12669-ent-0329" valign="top" rowspan="1" colspan="1">&#x02212;4.4 (1.9)<xref ref-type="fn" rid="dom12669-note-0003">*</xref>
</td><td align="left" id="dom12669-ent-0330" valign="top" rowspan="1" colspan="1">1.2 (2.0)</td><td align="left" id="dom12669-ent-0331" valign="top" rowspan="1" colspan="1">1.6 (3.0)</td><td align="left" id="dom12669-ent-0332" valign="top" rowspan="1" colspan="1">&#x02212;0.1 (2.6)</td></tr><tr><td align="left" style="padding-left:10%" id="dom12669-ent-0333" valign="top" rowspan="1" colspan="1">DBP, mmHg</td><td align="left" id="dom12669-ent-0334" valign="top" rowspan="1" colspan="1">&#x02212;1.5 (1.0)</td><td align="left" id="dom12669-ent-0335" valign="top" rowspan="1" colspan="1">&#x02212;2.1 (1.2)</td><td align="left" id="dom12669-ent-0336" valign="top" rowspan="1" colspan="1">&#x02212;3.4 (1.3)<xref ref-type="fn" rid="dom12669-note-0003">*</xref>
</td><td align="left" id="dom12669-ent-0337" valign="top" rowspan="1" colspan="1">3.0 (1.0)<xref ref-type="fn" rid="dom12669-note-0003">*</xref>
</td><td align="left" id="dom12669-ent-0338" valign="top" rowspan="1" colspan="1">1.2 (1.6)</td><td align="left" id="dom12669-ent-0339" valign="top" rowspan="1" colspan="1">0.2 (1.4)</td></tr><tr><td align="left" style="padding-left:10%" id="dom12669-ent-0340" valign="top" rowspan="1" colspan="1">LDL cholesterol, mmol/l</td><td align="left" id="dom12669-ent-0341" valign="top" rowspan="1" colspan="1">0.0 (0.17)</td><td align="left" id="dom12669-ent-0342" valign="top" rowspan="1" colspan="1">&#x02212;0.30 (0.10)<xref ref-type="fn" rid="dom12669-note-0003">*</xref>
</td><td align="left" id="dom12669-ent-0343" valign="top" rowspan="1" colspan="1">&#x02212;0.09 (0.10)</td><td align="left" id="dom12669-ent-0344" valign="top" rowspan="1" colspan="1">0.14 (0.10)</td><td align="left" id="dom12669-ent-0345" valign="top" rowspan="1" colspan="1">0.04 (0.10)</td><td align="left" id="dom12669-ent-0346" valign="top" rowspan="1" colspan="1">0.0 (0.11)</td></tr><tr><td align="left" style="padding-left:10%" id="dom12669-ent-0347" valign="top" rowspan="1" colspan="1">HDL cholesterol, mmol/l</td><td align="left" id="dom12669-ent-0348" valign="top" rowspan="1" colspan="1">&#x02212;0.05 (0.03)</td><td align="left" id="dom12669-ent-0349" valign="top" rowspan="1" colspan="1">0 (0.02)</td><td align="left" id="dom12669-ent-0350" valign="top" rowspan="1" colspan="1">0.04 (0.01)<xref ref-type="fn" rid="dom12669-note-0003">*</xref>
</td><td align="left" id="dom12669-ent-0351" valign="top" rowspan="1" colspan="1">&#x02212;0.01 (0.09)</td><td align="left" id="dom12669-ent-0352" valign="top" rowspan="1" colspan="1">0 (0.03)</td><td align="left" id="dom12669-ent-0353" valign="top" rowspan="1" colspan="1">&#x02212;0.01 (0.02)</td></tr><tr><td align="left" style="padding-left:10%" id="dom12669-ent-0354" valign="top" rowspan="1" colspan="1">LDL cholesterol/HDL cholesterol ratio, mmol/l</td><td align="left" id="dom12669-ent-0355" valign="top" rowspan="1" colspan="1">0.11 (0.15)</td><td align="left" id="dom12669-ent-0356" valign="top" rowspan="1" colspan="1">&#x02212;0.31 (0.11)<xref ref-type="fn" rid="dom12669-note-0003">*</xref>
</td><td align="left" id="dom12669-ent-0357" valign="top" rowspan="1" colspan="1">&#x02212;0.13 (0.09)</td><td align="left" id="dom12669-ent-0358" valign="top" rowspan="1" colspan="1">0.13 (0.13)</td><td align="left" id="dom12669-ent-0359" valign="top" rowspan="1" colspan="1">0.05 (0.08)</td><td align="left" id="dom12669-ent-0360" valign="top" rowspan="1" colspan="1">&#x02212;0.02 (0.12)</td></tr><tr><td align="left" style="padding-left:10%" id="dom12669-ent-0361" valign="top" rowspan="1" colspan="1">Total cholesterol, mmol/l</td><td align="left" id="dom12669-ent-0362" valign="top" rowspan="1" colspan="1">0.03 (0.18)</td><td align="left" id="dom12669-ent-0363" valign="top" rowspan="1" colspan="1">&#x02212;0.28 (0.11)<xref ref-type="fn" rid="dom12669-note-0003">*</xref>
</td><td align="left" id="dom12669-ent-0364" valign="top" rowspan="1" colspan="1">&#x02212;0.08 (0.13)</td><td align="left" id="dom12669-ent-0365" valign="top" rowspan="1" colspan="1">0.14 (0.11)</td><td align="left" id="dom12669-ent-0366" valign="top" rowspan="1" colspan="1">0.08 (0.11)</td><td align="left" id="dom12669-ent-0367" valign="top" rowspan="1" colspan="1">&#x02212;0.01 (0.12)</td></tr><tr><td align="left" style="padding-left:10%" id="dom12669-ent-0368" valign="top" rowspan="1" colspan="1">Triglycerides, mmol/l, median</td><td align="left" id="dom12669-ent-0369" valign="top" rowspan="1" colspan="1">0.10</td><td align="left" id="dom12669-ent-0370" valign="top" rowspan="1" colspan="1">&#x02212;0.17</td><td align="left" id="dom12669-ent-0371" valign="top" rowspan="1" colspan="1">0.04</td><td align="left" id="dom12669-ent-0372" valign="top" rowspan="1" colspan="1">&#x02212;0.02</td><td align="left" id="dom12669-ent-0373" valign="top" rowspan="1" colspan="1">&#x02212;0.02</td><td align="left" id="dom12669-ent-0374" valign="top" rowspan="1" colspan="1">&#x02212;0.04</td></tr><tr><td align="left" id="dom12669-ent-0375" valign="top" rowspan="1" colspan="1">Patients achieving HbA1c &#x0003c;7.0% (&#x0003c;53 mmol/mol) at endpoint, n (%)</td><td align="left" id="dom12669-ent-0376" valign="top" rowspan="1" colspan="1">16 (44.4)</td><td align="left" id="dom12669-ent-0377" valign="top" rowspan="1" colspan="1">33 (66.0)</td><td align="left" id="dom12669-ent-0378" valign="top" rowspan="1" colspan="1">25 (49.0)</td><td align="left" id="dom12669-ent-0379" valign="top" rowspan="1" colspan="1">11 (25.6)</td><td align="left" id="dom12669-ent-0380" valign="top" rowspan="1" colspan="1">10 (28.6)</td><td align="left" id="dom12669-ent-0381" valign="top" rowspan="1" colspan="1">13 (29.5)</td></tr><tr><td align="left" id="dom12669-ent-0382" valign="top" rowspan="1" colspan="1">Patients achieving HbA1c &#x0003c;7.0% (&#x0003c;53 mmol/mol) and no weight gain at endpoint, n (%)</td><td align="left" id="dom12669-ent-0383" valign="top" rowspan="1" colspan="1">10 (27.8)</td><td align="left" id="dom12669-ent-0384" valign="top" rowspan="1" colspan="1">25 (50.0)</td><td align="left" id="dom12669-ent-0385" valign="top" rowspan="1" colspan="1">20 (39.2)</td><td align="left" id="dom12669-ent-0386" valign="top" rowspan="1" colspan="1">5 (11.6)</td><td align="left" id="dom12669-ent-0387" valign="top" rowspan="1" colspan="1">8 (22.9)</td><td align="left" id="dom12669-ent-0388" valign="top" rowspan="1" colspan="1">8 (18.2)</td></tr></tbody></table><table-wrap-foot><fn id="dom12669-note-0002"><p>Data are mean (standard error) unless otherwise stated. <styled-content style="fixed-case">BMI</styled-content>, body mass index; <styled-content style="fixed-case">BP</styled-content>, blood pressure; <styled-content style="fixed-case">DBP</styled-content>, diastolic blood pressure; <styled-content style="fixed-case">FPG</styled-content>, fasting plasma glucose; <styled-content style="fixed-case">HbA1c</styled-content>, glycated haemoglobin; <styled-content style="fixed-case">SBP</styled-content>, systolic blood pressure.</p></fn><fn id="dom12669-note-0003"><label>*</label><p>p &#x0003c; 0.05.</p></fn></table-wrap-foot></table-wrap><p id="dom12669-para-0049">Body weight was significantly reduced among patients receiving add&#x02010;on exenatide twice daily across all groups except the &#x0003c;30 kg/m<sup>2</sup> BMI group in the placebo&#x02010;controlled study (p &#x0003c; 0.05; Table <xref rid="dom12669-tbl-0002" ref-type="table-wrap">2</xref>). Increases in body weight were observed for both comparators. Baseline BMI was not correlated with changes from baseline in body weight for any treatment in either study (range of <italic>r</italic>&#x02010;values, &#x02212;0.18 to 0.09). Achievement of HbA1c &#x0003c;7.0% (&#x0003c;53 mmol/mol) and no weight gain was consistently higher for patients receiving exenatide twice daily versus comparator in both studies (Table <xref rid="dom12669-tbl-0002" ref-type="table-wrap">2</xref>).</p><p id="dom12669-para-0050">When excluding patients who added on new antihypertensive medications (lispro&#x02010;comparator study: exenatide twice daily, n = 2; insulin lispro, n = 5; placebo&#x02010;controlled study: exenatide twice daily, n = 14; placebo, n = 14), the BP&#x02010;lowering effect of add&#x02010;on exenatide twice daily remained and changes in BP observed were similar to those in the overall ITT populations of the BMI range groups (Table <xref rid="dom12669-tbl-0002" ref-type="table-wrap">2</xref>). Baseline BMI was not correlated with changes from baseline in SBP (range of <italic>r</italic>&#x02010;values, &#x02212;0.03 to &#x02212;0.11) or diastolic BP (range of <italic>r</italic>&#x02010;values, &#x02212;0.08 to &#x02212;0.14) for any treatment in either study.</p><p id="dom12669-para-0051">None of the patients in the lispro&#x02010;comparator study added on new lipid&#x02010;lowering medications after randomization. In the placebo&#x02010;controlled study, 10 patients receiving exenatide twice daily and zero placebo&#x02010;treated patients added on lipid&#x02010;lowering medications. When excluding these patients, the changes from baseline in LDL cholesterol, HDL cholesterol and total cholesterol were similar to those in the overall ITT population of each BMI range group. Baseline BMI was not correlated with changes in LDL cholesterol, HDL cholesterol, total cholesterol, or triglycerides for any treatment in either study (range of <italic>r</italic>&#x02010;values for all lipids, &#x02212;0.14 to 0.24).</p></sec><sec id="dom12669-sec-0008"><title>Safety and Tolerability</title><p id="dom12669-para-0052">Rates of minor hypoglycaemia were numerically lower among patients receiving add&#x02010;on exenatide twice daily versus add&#x02010;on insulin lispro in all BMI range groups in the lispro&#x02010;comparator study and versus placebo in the lowest BMI range groups in the placebo&#x02010;controlled study (Table S1, Supporting Information). Major hypoglycaemia was infrequent and occurred in a smaller proportion of patients receiving exenatide twice daily versus insulin lispro in the lispro&#x02010;comparator study; major hypoglycaemia was not reported in the placebo&#x02010;controlled study for exenatide twice daily. The most frequent TEAEs (&#x02265;10% incidence) by preferred term included diarrhoea, nausea, vomiting and nasopharyngitis in the lispro&#x02010;comparator study, and nausea, diarrhoea and vomiting in the placebo&#x02010;controlled study.</p></sec></sec><sec id="dom12669-sec-0009"><title>Discussion</title><p id="dom12669-para-0053">In this secondary analysis of two clinical trials in which patients with T2D were randomized to add&#x02010;on exenatide twice daily versus add&#x02010;on insulin lispro or placebo, while taking background insulin glargine with or without metformin and/or pioglitazone, baseline BMI was not correlated with changes from baseline in the efficacy variables evaluated. In both studies, exenatide twice daily was associated with significant reductions in HbA1c and body weight. In the lispro&#x02010;comparator study, HbA1c reductions were equivalent for exenatide twice daily and insulin lispro; however, insulin lispro was associated with significant weight gain. Thus, the decision by some European national authorities or health insurance companies to restrict GLP&#x02010;1RA reimbursement to patients with BMI &#x0003e;35 kg/m<sup>2</sup> is not consistent with medical evidence.</p><p id="dom12669-para-0054">Other studies of exenatide twice daily have also found similar efficacy across BMI subgroups. In <italic>post hoc</italic> analyses of exenatide twice daily (16 randomized controlled trials), HbA1c, body weight and SBP reductions were significant for all BMI range groups (p &#x0003c; 0.0001) <xref rid="dom12669-bib-0010" ref-type="ref">10</xref>, <xref rid="dom12669-bib-0011" ref-type="ref">11</xref>. Similarly, studies with liraglutide <xref rid="dom12669-bib-0012" ref-type="ref">12</xref> and lixisenatide added on to basal insulin <xref rid="dom12669-bib-0013" ref-type="ref">13</xref> have reported reductions in HbA1c and body weight across BMI range groups. These effects appear to complement the guideline&#x02010;recommended management of cardiovascular risk factors.</p><p id="dom12669-para-0055">Hypoglycaemia is a concern in patients with T2D taking both basal and mealtime insulins <xref rid="dom12669-bib-0014" ref-type="ref">14</xref>, <xref rid="dom12669-bib-0015" ref-type="ref">15</xref>, and exenatide twice daily added to background insulin glargine appeared to mitigate this risk. The trend of fewer minor hypoglycaemic events in patients with BMI &#x0003c;30 kg/m<sup>2</sup> receiving exenatide twice daily treatment versus comparators in both studies is important because low BMI (25 vs 35 kg/m<sup>2</sup>) is associated with increased non&#x02010;severe hypoglycaemia risk in patients with T2D <xref rid="dom12669-bib-0016" ref-type="ref">16</xref>. In both studies and for all BMI range groups, exenatide twice daily treatment was associated with an increased rate of gastrointestinal TEAEs versus comparator.</p><p id="dom12669-para-0056">Limitations of the present analysis include differences in study design, the retrospective nature of the analysis, and the lack of balance across BMI range groups.</p><p id="dom12669-para-0057">In conclusion, recent international guidelines have adopted a more favourable opinion on the combination of basal insulin and GLP&#x02010;1RAs after basal insulin failure. Exenatide twice daily effectively reduced HbA1c and body weight across BMI range groups, including patients with near&#x02010;normal BMI, and was well tolerated with a low risk of hypoglycaemia. Changes in efficacy variables were not significantly correlated with baseline BMI. There is evidence of clinically meaningful glycaemic and weight benefits from the addition of exenatide twice daily to insulin glargine in both patients of normal weight and patients with mild to severe obesity, and there does not appear to be a threshold below which exenatide twice daily is not effective. Limiting reimbursement to patients with obesity (BMI &#x0003e;35 kg/m<sup>2</sup>) may result in the undertreatment of patients with lower BMI and may increase their risk of hypoglycaemia and unwanted weight gain.</p></sec><sec id="dom12669-sec-0011"><title>Conflict of Interest</title><p id="dom12669-para-0059">B. H. R. W. has received grant support for clinical studies and also consulting fees for serving on advisory boards and has served as a speaker for AstraZeneca, Eli Lilly and Company, GlaxoSmithKline, Novo Nordisk, Pfizer and Sanofi Aventis. He has also received consulting fees from Eli Lilly and Company as a member of the 4B Study and of the DURABLE Trial Data Monitoring Committee, and grant support from the European Union (BBMRI, BioSHaRE, and MDS&#x02010;Right Consortiums), JDRF and Diabetes Fonds Nederland. L. V. G. is/has been a member of the advisory boards and speakers' bureaus for AstraZeneca/BMS, Boehringer Ingelheim, Eli Lilly, Janssen, Johnson &#x00026; Johnson, Merck MSD, Novo Nordisk and Sanofi (2011&#x02013;2013). He also received grant support from the European Union (Hepadip &#x00026; Resolve Consortium) and National Research Funds, Belgium. S. D. G. has received grant support for clinical studies from AstraZeneca, Eli Lilly and Company, GlaxoSmithKline, Intarcia, Lexicon, Novo Nordisk, Pfizer, Servier, and Takeda. J. H. has received consulting fees for statistical consulting.</p><p id="dom12669-para-0060">B. H. R. W. and L. V. G. were investigators in the 4B Study Group, B. H. R. W., L. V. G., S. D. G. and J. H. conceived the analysis and participated in the writing of the manuscript. All authors approved the final version of the manuscript.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material content-type="local-data" id="dom12669-supitem-0001"><caption><p id="dom12669-para-0001">
<bold>Figure S1.</bold> Study design.</p><p id="dom12669-para-0002">
<bold>Table S1.</bold> Treatment&#x02010;emergent adverse events occurring in &#x02265;10% of patients in any group and hypoglycaemic events, according to baseline body mass index range group (intent&#x02010;to&#x02010;treat population).</p></caption><media xlink:href="DOM-18-829-s001.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack id="dom12669-sec-0010"><title>Acknowledgements</title><p id="dom12669-para-0058">The studies included in the analysis were supported by the alliance of Eli Lilly and Company and Amylin Pharmaceuticals and the alliance of Bristol&#x02010;Myers Squibb and AstraZeneca. Manuscript development was supported by AstraZeneca. Raewyn Poole and Robert Schupp, PharmD, CMPP, of inScience Communications, Springer Healthcare (Philadelphia, PA, USA), provided medical writing support funded by AstraZeneca.</p></ack><ref-list content-type="cited-references" id="dom12669-bibl-0001"><title>References</title><ref id="dom12669-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="dom12669-cit-0001">
<string-name>
<surname>Inzucchi</surname>
<given-names>SE</given-names>
</string-name>, <string-name>
<surname>Bergenstal</surname>
<given-names>RM</given-names>
</string-name>, <string-name>
<surname>Buse</surname>
<given-names>JB</given-names>
</string-name> et al. <article-title>Management of hyperglycemia in type 2 diabetes, 2015: a patient&#x02010;centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes</article-title>. <source>Diabetes Care</source>
<year>2015</year>; <volume>38</volume>: <fpage>140</fpage>&#x02013;<lpage>149</lpage>.<pub-id pub-id-type="pmid">25538310</pub-id></mixed-citation></ref><ref id="dom12669-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="dom12669-cit-0002">
<string-name>
<surname>Diamant</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Nauck</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Shaginian</surname>
<given-names>R</given-names>
</string-name> et al. <article-title>Glucagon&#x02010;like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes</article-title>. <source>Diabetes Care</source>
<year>2014</year>; <volume>37</volume>: <fpage>2763</fpage>&#x02013;<lpage>2773</lpage>.<pub-id pub-id-type="pmid">25011946</pub-id></mixed-citation></ref><ref id="dom12669-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="dom12669-cit-0003">
<string-name>
<surname>Gough</surname>
<given-names>SC</given-names>
</string-name>, <string-name>
<surname>Bode</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Woo</surname>
<given-names>V</given-names>
</string-name> et al. <article-title>Efficacy and safety of a fixed&#x02010;ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open&#x02010;label, randomised, 26&#x02010;week, treat&#x02010;to&#x02010;target trial in insulin&#x02010;naive patients with type 2 diabetes</article-title>. <source>Lancet Diabetes Endocrinol</source>
<year>2014</year>; <volume>2</volume>: <fpage>885</fpage>&#x02013;<lpage>893</lpage>.<pub-id pub-id-type="pmid">25190523</pub-id></mixed-citation></ref><ref id="dom12669-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="dom12669-cit-0004">
<string-name>
<surname>Rosenstock</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Fonseca</surname>
<given-names>VA</given-names>
</string-name>, <string-name>
<surname>Gross</surname>
<given-names>JL</given-names>
</string-name> et al. <article-title>Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP&#x02010;1 receptor agonist, versus thrice&#x02010;daily prandial insulin lispro</article-title>. <source>Diabetes Care</source>
<year>2014</year>; <volume>37</volume>: <fpage>2317</fpage>&#x02013;<lpage>2325</lpage>.<pub-id pub-id-type="pmid">24898300</pub-id></mixed-citation></ref><ref id="dom12669-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="dom12669-cit-0005">
<string-name>
<surname>Divino</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>DeKoven</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Hallinan</surname>
<given-names>S</given-names>
</string-name> et al. <article-title>Glucagon&#x02010;like peptide&#x02010;1 receptor agonist treatment patterns among type 2 diabetes patients in six European countries</article-title>. <source>Diabetes Ther</source>
<year>2014</year>; <volume>5</volume>: <fpage>499</fpage>&#x02013;<lpage>520</lpage>.<pub-id pub-id-type="pmid">25366334</pub-id></mixed-citation></ref><ref id="dom12669-bib-0006"><label>6</label><mixed-citation publication-type="miscellaneous" id="dom12669-cit-0006">
<collab collab-type="authors" id="dom12669-gp-0001">National Institute for Health and Care Excellence</collab>
. <article-title>Type 2 diabetes&#x02014;the management of type 2 diabetes</article-title> (NICE clinical guideline 87, March 2014). London, <year>2014</year>.</mixed-citation></ref><ref id="dom12669-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="dom12669-cit-0007">
<string-name>
<surname>Buse</surname>
<given-names>JB</given-names>
</string-name>, <string-name>
<surname>Bergenstal</surname>
<given-names>RM</given-names>
</string-name>, <string-name>
<surname>Glass</surname>
<given-names>LC</given-names>
</string-name> et al. <article-title>Use of twice&#x02010;daily exenatide in basal insulin&#x02010;treated patients with type 2 diabetes: a randomized, controlled trial</article-title>. <source>Ann Intern Med</source>
<year>2011</year>; <volume>154</volume>: <fpage>103</fpage>&#x02013;<lpage>112</lpage>.<pub-id pub-id-type="pmid">21138825</pub-id></mixed-citation></ref><ref id="dom12669-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="dom12669-cit-0008">
<string-name>
<surname>Jensen</surname>
<given-names>MD</given-names>
</string-name>, <string-name>
<surname>Ryan</surname>
<given-names>DH</given-names>
</string-name>, <string-name>
<surname>Apovian</surname>
<given-names>CM</given-names>
</string-name> et al. <article-title>2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society</article-title>. <source>Circulation</source>
<year>2014</year>; <volume>129</volume>: <fpage>S102</fpage>&#x02013;<lpage>S138</lpage>.<pub-id pub-id-type="pmid">24222017</pub-id></mixed-citation></ref><ref id="dom12669-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="dom12669-cit-0009">
<string-name>
<surname>Tsigos</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Hainer</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Basdevant</surname>
<given-names>A</given-names>
</string-name> et al. <article-title>Management of obesity in adults: european clinical practice guidelines</article-title>. <source>Obes Facts</source>
<year>2008</year>; <volume>1</volume>: <fpage>106</fpage>&#x02013;<lpage>116</lpage>.<pub-id pub-id-type="pmid">20054170</pub-id></mixed-citation></ref><ref id="dom12669-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="dom12669-cit-0010">
<string-name>
<surname>Pencek</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Blickensderfer</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Brunell</surname>
<given-names>SC</given-names>
</string-name>, <string-name>
<surname>Anderson</surname>
<given-names>PW</given-names>
</string-name>. <article-title>Exenatide twice daily: analysis of effectiveness and safety data stratified by age, sex, race, duration of diabetes, and body mass index</article-title>. <source>Postgrad Med</source>
<year>2012</year>; <volume>124</volume>: <fpage>21</fpage>&#x02013;<lpage>32</lpage>.</mixed-citation></ref><ref id="dom12669-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="dom12669-cit-0011">
<string-name>
<surname>Rosenstock</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Shenouda</surname>
<given-names>SK</given-names>
</string-name>, <string-name>
<surname>Bergenstal</surname>
<given-names>RM</given-names>
</string-name> et al. <article-title>Baseline factors associated with glycemic control and weight loss when exenatide twice daily is added to optimized insulin glargine in patients with type 2 diabetes</article-title>. <source>Diabetes Care</source>
<year>2012</year>; <volume>35</volume>: <fpage>955</fpage>&#x02013;<lpage>958</lpage>.<pub-id pub-id-type="pmid">22432107</pub-id></mixed-citation></ref><ref id="dom12669-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="dom12669-cit-0012">
<string-name>
<surname>Chitnis</surname>
<given-names>AS</given-names>
</string-name>, <string-name>
<surname>Ganz</surname>
<given-names>ML</given-names>
</string-name>, <string-name>
<surname>Benjamin</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Langer</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Hammer</surname>
<given-names>M</given-names>
</string-name>. <article-title>Clinical effectiveness of liraglutide across body mass index in patients with type 2 diabetes in the United States: a retrospective cohort study</article-title>. <source>Adv Ther</source>
<year>2014</year>; <volume>31</volume>: <fpage>986</fpage>&#x02013;<lpage>999</lpage>.<pub-id pub-id-type="pmid">25245811</pub-id></mixed-citation></ref><ref id="dom12669-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="dom12669-cit-0013">
<string-name>
<surname>Eto</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Naito</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Seino</surname>
<given-names>Y</given-names>
</string-name>. <article-title>Evaluation of the efficacy and safety of lixisenatide add&#x02010;on treatment to basal insulin therapy among T2DM patients with different body mass indices from GetGoal trials</article-title>. <source>Diabetol Metab Syndr</source>
<year>2015</year>; <volume>7</volume>: <fpage>106</fpage>.<pub-id pub-id-type="pmid">26594250</pub-id></mixed-citation></ref><ref id="dom12669-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="dom12669-cit-0014">
<string-name>
<surname>Rodbard</surname>
<given-names>HW</given-names>
</string-name>, <string-name>
<surname>Cariou</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Zinman</surname>
<given-names>B</given-names>
</string-name> et al. <article-title>Comparison of insulin degludec with insulin glargine in insulin&#x02010;naive subjects with type 2 diabetes: a 2&#x02010;year randomized, treat&#x02010;to&#x02010;target trial</article-title>. <source>Diabet Med</source>
<year>2013</year>; <volume>30</volume>: <fpage>1298</fpage>&#x02013;<lpage>1304</lpage>.<pub-id pub-id-type="pmid">23952326</pub-id></mixed-citation></ref><ref id="dom12669-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="dom12669-cit-0015">
<string-name>
<surname>Wang</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Mamza</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Idris</surname>
<given-names>I</given-names>
</string-name>. <article-title>Biphasic vs basal bolus insulin regimen in type 2 diabetes: a systematic review and meta&#x02010;analysis of randomized controlled trials</article-title>. <source>Diabet Med</source>
<year>2015</year>; <volume>32</volume>: <fpage>585</fpage>&#x02013;<lpage>594</lpage>.<pub-id pub-id-type="pmid">25594251</pub-id></mixed-citation></ref><ref id="dom12669-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="dom12669-cit-0016">
<collab collab-type="authors" id="dom12669-gp-0002">Origin Trial Investigators</collab>
. <article-title>Predictors of nonsevere and severe hypoglycemia during glucose&#x02010;lowering treatment with insulin glargine or standard drugs in the ORIGIN trial</article-title>. <source>Diabetes Care</source>
<year>2015</year>; <volume>38</volume>: <fpage>22</fpage>&#x02013;<lpage>28</lpage>.<pub-id pub-id-type="pmid">25352653</pub-id></mixed-citation></ref></ref-list></back></article>